Glenmark bags USFDA nod for Metronidazole Vaginal Gel

Published On 2022-01-28 05:42 GMT   |   Update On 2022-01-28 05:42 GMT

Mumbai: Drug maker, Glenmark Pharmaceuticals Inc., USA  has received final approval from the United States Food & Drug Administration (USFDA) for Metronidazole Vaginal Gel, 0.75%.

The product is a generic version of MetroGel-Vaginal Gel, 0.75%, of Bausch Health US, LLC.

According to IQVIA sales data for the 12 month period ending November 2021, the MetroGel- Vaginal Gel, 0.75% market achieved annual sales of approximately $60.4 million*.
Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Read also: Glenmark bags USFDA nod for generic version of Ziac Tablets

Advertisement

Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries.

Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for four consecutive years in a row; most recently in 2021.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News